Therefore, inferences made from the findings in Figure 5 confirm that ALX and FSK treatment enhanced the resolution of maladaptive myocardial inflammation by inhibiting GRK5-mediated inflammation and synergistic enhancement of cAMP bioavailability which exerted adaptive immunoregulation and promoted recovery from ICM. The gene discussed is GRK5; the disease is inflammatory response.